Biotech Startups

Alafair Biosciences develops advanced bioresorbable biomaterials for surgical soft tissue healing and motion preservation. The company serves surgeons and patients undergoing procedures requiring post-surgical recovery, with a focus on preventing tissue tethering and supporting natural mobility.

3 investors

Identifies, develops, and manufactures novel antibody therapeutics for autoimmune and inflammatory diseases.

3 investors

An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease. The company operates manufacturing facilities in China and has established commercial networks across major Chinese cities and hospitals.

3 investors

Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.

3 investors

Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.

3 investors

Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve. Its Staccato platform and assets were acquired by Lee's Pharmaceutical Holdings.

3 investors

AlgaFilm develops an algae-based biofilm technology for wastewater treatment that recovers nutrients as a sustainable alternative to conventional treatment methods. The company targets wastewater utilities and treatment facilities globally with its innovative process.

3 investors

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.

3 investors

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.

3 investors

All G produces high-value proteins using precision fermentation technology for infant formula, dietary supplements, and personal care applications. The company manufactures lactoferrin and human milk proteins at scale while maintaining infant formula-grade purity and quality standards for global markets.

3 investors

Develops non-systemic protein therapeutics for metabolic and orphan diseases (NASDAQ: ALNA).

3 investors

Allevi, part of 3D Systems, makes desktop 3D bioprinters and bioinks used by academic and industry research labs to design and engineer 3D tissues. Its tools support work in regenerative medicine, drug testing, and disease research.

3 investors

Allonnia applies industrial biology—screening microbes and engineered proteins that interact with metals—to recover copper, nickel, and rare earths from ore and mine waste streams like coal ash, tailings, and acid mine drainage. Its bolt-on systems (D-Solve and RE-Cover) attach to existing mine flowsheets for mining operators to increase metal grade and recovery.

3 investors

3 investors

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.

3 investors

LivaNova develops medical devices and therapies aimed at treating conditions such as epilepsy (seizures), sleep disorders, depression, and cardiac conditions. It operates in the medical technology industry, serving patients and healthcare providers.

3 investors

Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.

3 investors

AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.

3 investors

Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.

3 investors

Amino Collective is an early-stage venture capital firm that invests in health and biotechnology companies at the pre-seed and seed stages. The firm operates with a concentrated investment approach, typically backing a small number of companies annually.

3 investors

AmplifiDx develops point-of-care molecular diagnostic tests and its DX 100 platform for family, women's, and sexual health, targeting infectious disease detection for healthcare professionals and patients. The multiplex platform can detect up to 10 analytes with rapid results and minimal hands-on time.

3 investors

AVS develops the Pulse IVL system, a medical device for treating calcified arterial disease using a unique mechanism of action for improved deliverability in peripheral and coronary applications.

3 investors

AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications. The company develops biomarker discovery tools and clinical research solutions for clinicians and researchers to enable earlier disease detection and targeted interventions.

3 investors

Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products. Founded in 2003, the company focuses on sustainable, bio-based sourcing of molecules.

3 investors